Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients ...
Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan ...
Pharmaceutical Technology2 天
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.